Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia
- Cancer
- Breast Cancer
Completed
- Saudi Arabia
NCT02954471 ML29903
Trial Summary
This is a retrospective, multicenter study, consisting of chart review of Saudi Arabian participants diagnosed with breast cancer between 2007 and 2013 and with available human epidermal growth factor receptor 2 (HER2) testing. Data on survival will be collected through 2015.
A Retrospective, Observational Molecular Epidemiology Study of HER2 Expression in Patients With Early / Metastatic Breast Cancer in Saudi Arabia
Eligibility Criteria
- Initially diagnosed with breast cancer
- Has a proven result of HER2 testing by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) or any other in situ hybridization (ISH) method
- Alive or not alive
- Inconclusive, equivocal or unavailable result of HER2/neu overexpression by IHC and FISH
For the latest version of this information please go to www.forpatients.roche.com